Related references
Note: Only part of the references are listed.Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Fabio Stagno et al.
ACTA ONCOLOGICA (2010)
Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis
Fausto Castagnetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2009)
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Nicoletta Testoni et al.
BLOOD (2009)
Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9
Ayda Bennour et al.
CANCER GENETICS AND CYTOGENETICS (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
Susan Branford et al.
BLOOD (2008)
Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements
Valeria A. S. De Melo et al.
CANCER GENETICS AND CYTOGENETICS (2008)
Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy
Steven Richebourg et al.
CANCER GENETICS AND CYTOGENETICS (2008)
A PROSPECTIVE RANDOMIZED STUDY OF IMATINIB 400 MG VS 800 MG AS A FRONTLINE THERAPY IN SOKAL HIGH RISK (HR) PH-POS CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
M. Baccarani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
M. C. Mueller et al.
LEUKEMIA (2008)
Home-brew FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia
Francesco Albano et al.
CANCER GENETICS AND CYTOGENETICS (2007)
On the genesis and prognosis of variant translocations in chronic myeloid leukemia
Madhavi Gorusu et al.
CANCER GENETICS AND CYTOGENETICS (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Conventional cytogenetics and FISH in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML)
Hon Fong L. Mark et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2006)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia
Antonella Zagaria et al.
CANCER GENETICS AND CYTOGENETICS (2006)
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
MMT El-Zimaity et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects
VHJ van der Velden et al.
LEUKEMIA (2003)
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
JE Cortes et al.
BLOOD (2003)
Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia
AG Reid et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Heterogenic molecular basis for loss of ABL I-BCR transcription:: Deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABLI-positive chronic myeloid leukemia
IF Loncarevic et al.
GENES CHROMOSOMES & CANCER (2002)
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia
B Johansson et al.
ACTA HAEMATOLOGICA (2002)
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
BJP Huntly et al.
BLOOD (2001)
Share Paper
